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Abstract
Chronic liver diseases are characterized by a sustained inflammatory response in which
chemokines and chemokine-receptors orchestrate inflammatory cell recruitment. In this
study we investigated the role of the chemokine receptor CCR6 in acute and chronic liver
injury. In the absence of liver injury Ccr6-/- mice presented a higher number of hepatic mac-
rophages and increased expression of pro-inflammatory cytokines and M1 markers Tnf-α,
Il6 andMcp1. Inflammation and cell recruitment were increased after carbon tetrachloride-
induced acute liver injury in Ccr6-/- mice. Moreover, chronic liver injury by carbon tetrachlo-
ride in Ccr6-/- mice was associated with enhanced inflammation and fibrosis, altered macro-
phage recruitment, enhanced CD4+ cells and a reduction in Th17 (CD4+IL17+) and mature
dendritic (MHCII+CD11c+) cells recruitment. Clodronate depletion of macrophages in
Ccr6-/- mice resulted in a reduction of hepatic pro-inflammatory and pro-fibrogenic markers
in the absence and after liver injury. Finally, increased CCR6 hepatic expression in patients
with alcoholic hepatitis was found to correlate with liver expression of CCL20 and severity of
liver disease. In conclusion, CCR6 deficiency affects hepatic inflammatory cell recruitment
resulting in the promotion of hepatic inflammation and fibrosis.
Introduction
Alcoholic liver disease (ALD), non-alcoholic liver steatohepatitis (NASH) and viral infections
represent some of the most common chronic injuries that promote liver inflammation, fibrosis
and cirrhosis. The interplay between inflammatory damage and altered matrix deposition
causes the slow accumulation of scar matrix, leading to progressive fibrosis and cirrhosis [1].
Cirrhosis is a severe clinical condition associated with bad prognosis, which can progress to
hepatocellular carcinoma (HCC), one of the major causes of liver-related death worldwide [2].
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There are currently no therapies available to treat cirrhosis, and despite recent studies having
shown that it may be a reversible process, its resolution is still not achievable[1, 3]. In order to
prevent the development of cirrhosis, it is important to further investigate the mechanisms
leading to this severe condition. Alcoholic hepatitis (AH) is one of the most severe conditions
in ALD and a cause of acute-on-chronic liver failure. It is associated with short term-mortality
and characterized by hepatocellular damage and strong inflammatory response [4, 5].
Chemokines are small chemotactic molecules, which elicit their effects by binding and acti-
vating their transmembrane receptors. Several studies have shown that the deletion of specific
chemokines or chemokine-receptors can affect liver pathophysiology favoring either promo-
tion or inhibition of hepatic inflammation and fibrosis, thereby drawing attention to their use
for therapeutic purposes [6, 7]. Moreover, studies in experimental models have revealed that
chemokines and chemokine-receptors [8] play an important role in hepatic inflammation and
fibrosis by orchestrating the inflammatory recruitment of different cell populations including
macrophages, dendritic cells and T cells to the injured liver [9–11]. Several studies have also
shown that chemokines and chemokine-receptors are differentially regulated in ALD suggest-
ing that they may be important mediators in the progression of the disease [12–14]. Hepatic
macrophages are well-known inflammatory cell populations involved in the pathogenesis of
chronic liver diseases. They have been described to be important mediators of hepatic inflam-
mation and fibrosis, participating in both progression and regression of fibrosis [15–17].
Therefore, macrophages have been recently been proposed as new potential targets to develop
anti-fibrotic therapies [18].
In a recent study by our group we showed that chemokine CCL20 is a driver of hepatic
inflammation and fibrosis in patients with AH, providing evidence that CCL20 mediates
inflammatory cell recruitment upon liver injury by promoting hepatic infiltration of macro-
phages and neutrophils [19]. Chemokine receptor 6 (CCR6) is the only receptor described for
the chemokine CCL20. CCR6 has been shown to be expressed in different inflammatory cells
including CD4 T-cells and specifically in T-helper (Th)17 and T-regulatory (Treg) cells [20–
23], dendritic cells [24, 25] and also in γδ T cells [26, 27]. Importantly, a recent study showed
that CCR6-dependent accumulation of IL-17 producing γδ T cells restricts hepatic inflamma-
tion and fibrosis [28]. Nevertheless, the role of CCR6 during liver injury and how CCR6-de-
pendent infiltrated cells mediate the progression of hepatic inflammation and fibrosis in
response to liver injury is still largely unknown.
In this study we investigated the role of CCR6 in both acute and chronic liver injury. First,
we showed that CCR6 deficiency affected hepatic inflammatory cell recruitment in both the
absence and presence of liver damage. Moreover, CCR6 deficiency promoted exacerbated
inflammation and fibrosis in experimental models of liver injury. Second, we provided evi-
dences that the presence of both macrophages and CCR6-recruited cells is required for an ade-
quate response to liver injury. Finally, in a cohort of patients with AH we showed the
association between CCR6 hepatic expression and cirrhosis and its correlation with clinical
scores of disease severity.
Materials and Methods
Ethics statement
All protocols were conformed to the ethical guidelines of the 1975 Declaration of Helsinki and
were approved by the Ethics Committee of the Hospital Clinic of Barcelona. All the patients
included in this study provided written and signed informed consent.
All animal procedures were approved by the Investigation and Ethics Committee of Animal
Experimentation of the University of Barcelona and were conducted in accordance with the
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National Institutes of Health Guide for the Care and Use of Laboratory Animals. Euthanasia of
animals used in this study was performed by overdose of a cocktail mix composed by an anaes-
thetic (ketamine) and an analgesic (xylazine).
Experimental models of liver injury
Briefly, C57Bl/6 wild type (wt) and Ccr6 knock out (Ccr6-/-)mice aged 8–12 weeks, were
administered carbon tetrachloride (CCl4) to induce acute or chronic liver injury. Mononuclear
inflammatory cells were isolated from the liver of mice chronically treated with CCl4, and were
stained and analyzed by flow cytometry. The depletion of macrophages was performed by clo-
dronate liposomes (clodronateliposomes.org, Amsterdam, The Netherlands) before injecting
mice with vehicle (corn oil) or CCl4 to induce acute liver damage. The assessment of liver
inflammation and fibrosis was performed by immunohistochemistry and Sirius red staining,
respectively. All procedures are extensively described in S1 Text.
Patients
CCR6 hepatic gene expression was determined in 46 liver samples obtained by transjugular
biopsy from patients with AH. The patients prospectively included in the study were admitted
to the Liver Unit of the Hospital Clínic of Barcelona with clinical, analytical and histological
features of AH from July 2009 to January 2012. The inclusion and exclusion criteria of AH
have been previously described [19].
Statistical analysis
Results of quantitative variables are expressed as mean ± standard error unless otherwise speci-
fied. Comparisons between groups were performed using the Student´s t test or the Mann-
Whitney U test when appropriate. Correlations between variables were evaluated using Spear-
man’s Rho or Pearson’s r, when appropriate. Comparisons were performed by the log-rank
test. All statistical analyses were performed using SPSS version 14.0 for Windows (SPSS Inc.,
Chicago, IL).
Results
Ccr6 deficiency alters hepatic inflammatory recruitment in the absence
of liver damage and after acute liver injury
In order to investigate the role of CCR6 in liver injury, we evaluated inflammatory cell recruit-
ment in wt and Ccr6-/- mice in the absence and presence of liver injury. In the absence of dam-
age, Ccr6-/- mice showed increased hepatic levels of well-known pro-inflammatory and
macrophage-type1 (M1) markers such as Il6, Icam1, and Tnf-α (p<0.05) (Fig 1A). Moreover,
we also detected an increased number of macrophages in the liver of Ccr6-/- mice compared to
wt, as detected by F4/80 immunohistochemistry (p<0.05) (Fig 1B) and flow cytometry analyz-
ing the F4/80+CD11b+ cell population (28.4±11.2% Ccr6-/- vs. 13±2.3% wt of total hepatic
mononuclear cells) (p<0.05) (Fig 1C).
To evaluate the effects of CCR6 during acute liver injury, mice were subjected to acute CCl4
treatment. In response to acute CCl4 administration, Ccr6-/- mice showed significantly
increased hepatic levels of the pro-inflammatory molecules Il6, Icam1, Tnf-α andMcp1 as com-
pared to wt (p<0.05) (Fig 1A). Importantly, we also observed a significant increase in neutro-
phil recruitment and increased inflammatory cell proliferation in Ccr6-/- mice subjected to
acute liver damage as assessed by myeloperoxidase (MPO) and Ki67 immunohistochemistry
respectively (p<0.05 for both) (Fig 1D and 1E). Finally, no changes in transaminases levels
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were observed in the absence of damage or after acute CCl4-induced liver injury. Moreover,
CCl4 induced an increase in LDH serum levels as compared to wt (p<0.05) in Ccr6-/- mice
(Fig 1F).
Ccr6-/- mice show increased fibrosis upon chronic liver injury
To investigate the role of CCR6 during fibrogenesis in early phases of fibrosis and in a well-
established fibrosis model, we assessed fibrosis in wt and Ccr6-/- animals by injecting mice with
CCl4 during 2 and 4 weeks. After two weeks of CCl4-induced chronic liver injury, Ccr6-/- mice
showed increased hepatic levels of pro-fibrogenic genes Col1a1 and Tgf-β and also increased
Icam1 compared to wt (p<0.05) (Fig 2A). Hepatic Ccl20 expression showed no differences in
Ccr6-/- compared to wt mice (Fig 2A). CCL20 protein expression was detected in hepatocytes
after CCl4-induced chronic liver injury in wt and Ccr6-/- mice (S1A Fig). No significant differ-
ences in the pro-inflammatory genes Il6 andMcp1 were observed between the two groups in
response to chronic liver injury (data not shown). The fibrosis level in Ccr6-/- mice was con-
firmed by Sirius Red staining. As shown in Fig 2B and 2C, we found a higher collagen deposi-
tion in the liver of Ccr6-/- mice after 2 and 4 weeks of chronic CCl4 treatment compared to wt
(p<0.05).
Inflammatory recruitment in Ccr6-/- mice in response to chronic liver
injury
Since macrophages were found to be increased in Ccr6-/- mice in the absence of liver damage,
we investigated the changes in macrophage population in Ccr6-/- and wt mice after chronic
liver injury. Surprisingly, after induction of chronic liver injury we did not find any differences
in the number of total macrophages (F4/80+Cd11b+ positive cells) in the liver of Ccr6-/- com-
pared to wt (47±11.79% Ccr6-/- vs. 51±10.22% wt of total hepatic mononuclear cells) (Fig 2D)
as assessed by flow cytometry. However, a more detailed analysis showed a reduced number
of F4/80low/CD11bmid/high monocytes in Ccr6-/- mice compared to wt (11±3.7% Ccr6-/- vs.
25±5.3% wt of total hepatic mononuclear cells) (p<0.005) and a tendency to increase the infil-
trating monocyte-derived F4/80high/CD11bhigh macrophages (36±8.8% Ccr6-/- vs. 26±6.1%
wt of total hepatic mononuclear cells) (p = 0.08) which have been described to express Ly6C
and to be associate with liver injury and inflammation [11]. These results suggest an altered
inflammatory cell recruitment in Ccr6-/- mice with an increased proportion of infiltrated pro-
inflammatory macrophages (Fig 2D). According to these results, in the absence of injury we
detected a reduced hepatic expression of well-described anti-inflammatory macrophage-type 2
(M2) markers Il10 (p<0.05) andMgl1 (p = 0.12) in Ccr6-/- mice. No significant differences
were observed in Il10 and Mgl1 expression in Ccr6-/- mice compared with wt after chronic
treatment with CCl4 (Fig 2E).
In order to evaluate the effect of Ccr6 deficiency, inflammatory cell recruitment was evalu-
ated in wt and Ccr6-/- liver. After chronic CCl4 treatment, Ccr6-/- mice showed an increased
number of total CD4+T cells (13.14±4.7% Ccr6-/- vs. 5.56±2% wt of total hepatic mononuclear
Fig 1. CCR6 in acute liver injury. (A) Il6, Icam1, Tnf-α,Mcp1 hepatic gene expression in wt and Ccr6-/- (KO) mice in the absence (corn oil injected, n = 3
each group) and the presence of CCl4-induced acute liver injury (n = 4 each group) (*p<0.05 compared to wt). (B) Representative F4/80 immunostaining of
liver sections of wt andCcr6-/- (KO) mice (x200 magnification) in the absence of liver injury; F4/80 quantification of positive-stained areas in the absence
of liver injury is shown in the graph (*p<0.05 compared to wt). (C) Percentage of macrophages (F4/80+CD11b+) in wt andCcr6-/- mice (13±2.3% and
28.4±11.2% of total hepatic mononuclear cells respectively) in absence of liver injury. (D-E) Representative MPO and Ki67 immunostaining of liver sections
of wt andCcr6-/- (KO) mice (x200 magnification) in the absence (i) and presence (ii) of CCl4-induced acute liver injury; MPO and Ki67 quantification of
positive-stained areas is shown in the graph (*p<0.05 compared to wt). (F) ALT, AST and LDH serum levels in wt andCcr6-/- (KO) mice in the absence (ctrl
group) (corn oil injected, n = 3 each group) and presence of CCl4-induced acute liver injury (n = 4 each group) (*p<0.05 with respect to wt).
doi:10.1371/journal.pone.0145147.g001
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Fig 2. CCR6 in chronic liver injury. (A) Col1a1, Tgf-β, Icam1, Ccl20 hepatic gene expression in wt (n = 8) andCcr6-/- (KO) (n = 8) mice vehicle- (corn oil) or
CCl4–treated for two weeks (see S1 Text) (*p<0.05 with respect to wt). (B) Representative images of Sirius Red staining in livers of wt andCcr6-/- mice (x200
magnification) vehicle- (corn oil) or CCl4-treated for two and four weeks (see S1 Text). (C) Sirius Red quantification of positive-stained areas in vehicle- (corn
oil) and four-week CCl4-treated wt andCcr6-/- mice (*p<0.05 respect wt). (D) Representative FACS plots from livers of two weeks CCl4-treated mice
showing F4/80low/CD11bmid/high monocytes in wt andCcr6-/- mice (25±5.3% and 11±3.7% of total hepatic mononuclear cells, respectively) (p<0.005) and
F4/80high/CD11bhigh freshly infiltrating monocyte-derived macrophages in wt andCcr6-/-mice (26±6.1% and 36±8.8% of total hepatic mononuclear cells,
respectively) (p = 0.08). (E) Il10 andMgl1 hepatic gene expression in wt andCcr6-/- two-week vehicle- (corn oil) or CCl4–treated mice (*p<0.05 respect wt).
doi:10.1371/journal.pone.0145147.g002
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cells) (p<0.005), no differences in the hepatic recruitment of CD4+FOXP3+ regulatory T cells
(T-Reg) (22±5.5% Ccr6-/- vs. 19±8.3% wt of CD4+ cells), and a strong reduction in the number
of CD4+IL17+ (Th-17) cells (0.44±0.3% Ccr6-/- vs. 2.85±1.5% wt of CD4+ cells) (p = 0.005) as
compared to wt (Fig 3A) confirming that Ccr6 affects the hepatic T-cell recruitment [28]. To
better define if chronic liver injury drives the recruitment of profibrotic Th2 cells, we assessed
the hepatic levels of Th2 cytokines ll4 and Il13 as well as the Th2 transcription factor Gata3.
We did not find significant difference in ll4 and Gata3 hepatic expression between Ccr6-/- and
wt mice, and no Il13 expression was observed in the absence or presence of liver injury (S1B
Fig). These results suggest that no Th2 compensatory mechanism might be involved in Ccr6-/-
mice phenotype. To investigate hepatic neutrophil recruitment after liver injury, we stained wt
and Ccr6-/- liver samples with an MPO antibody. Interestingly, the hepatic number of MPO-
positive cells was lower in Ccr6-/- mice compared to wt after chronic liver injury (p<0.05)
(Fig 3B).
Finally, because dendritic cells have also been described to express CCR6 receptor, we inves-
tigated how CCR6 deficiency affected the hepatic recruitment of this cell population in
response to chronic liver injury. Using flow cytometry analysis we observed a decreased num-
ber of MHCII+CD11c+ positive cells (mature dendritic cells) in Ccr6-/- mice compared to wt in
the absence of liver injury (2.15±0.4% Ccr6-/- vs 3.05±0.5% wt of total hepatic mononuclear
cells) (p<0.05) and after chronic CCl4-induced liver damage (3.92±1.5% Ccr6-/- vs 5.91±1.5%
wt of total hepatic mononuclear cells) (p<0.05) (Fig 3C and 3D). No changes in the number of
B220+CD11c+ positive cells (immature dendritic cells) were found in any of the groups (data
not shown).
Macrophage depletion critically reduces the liver expression of pro-
inflammatory and pro-fibrogenic genes in Ccr6-/- mice
On finding an increased number of macrophages in the uninjured livers of Ccr6-/- mice, we
investigated whether macrophages might be responsible for the increased levels of inflamma-
tory mediators and the exacerbated inflammatory response observed in Ccr6-/- mice. Macro-
phages were depleted by injecting wt and Ccr6-/- mice intraperitoneally with clodronate- or
PBS-liposomes. The effect on hepatic inflammation and fibrosis was assessed after CCl4-in-
duced acute liver damage. The hepatic depletion of macrophages in the absence (data not
shown) and the presence of liver injury were assessed by F4/80 immunohistochemistry. Effects
of clodronate treatment were assessed by hematoxylin and eosin and F4/80 staining in liver
sections of Ccr6-/- and wt mice injected with vehicle (PBS liposomes) or clodronate liposomes
followed by one single intraperitoneal injection of CCl4. (Fig 4A and 4B). Quantification of
F4/80 positive cells in wt mice (24.36±2.74 F4/80+ cells/field in PBS liposomes plus CCl4 vs
0.25±0.26 F4/80+ cells/field in clodronate liposomes plus CCl4) and in Ccr6-/- mice (25.44±3.98
F4/80+ cells/field in PBS liposomes plus CCl4 vs 0.08±0.13 F4/80+ cells/field in clodronate
liposomes plus CCl4) confirmed the depletion of macrophages after clodronate treatment
(Fig 4A).
As shown in Fig 1A, Ccr6-/- mice presented increased levels of pro-inflammatory and pro-
fibrogenic genes. Interestingly, the depletion of macrophages by clodronate liposomes in
Ccr6-/- mice in the absence or after CCl4-induced acute liver damage induced a strong reduc-
tion of Icam1, Il6, Tnf-α, Nos2,Mcp1 and Col1a1 compared to control liposomes injected mice
(Fig 4C). Although clodronate liposome also induced a reduction of hepatic inflammatory
genes Il6, Tnf-α andMcp1 in wt mice (S2A Fig), macrophage depletion in Ccr6-/- mice lowered
inflammatory gene expression to that of wt mice or lower (Fig 4D). After acute CCl4 treatment
in macrophage-depleted animals, we observed a strong increase in LDH levels in both wt and
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in Ccr6-/- mice, but no significant differences were found between the two groups. No changes
in ALT and AST levels were detected between groups in the presence or the absence of macro-
phages (Fig 4E) suggesting that hepatocellular damage may not be affected. The response to
liver injury in mice after macrophage depletion was investigated only in acute liver injury set-
ting since Ccr6-/- mice treated with clodronate liposomes were extremely sensitive to CCl4
treatment, which induced at 24 hours a 62% mortality compared to the 12.5% observed in mac-
rophage-depleted and CCl4-injected wt mice. In order to understand the potential causes of an
increased mortality in Ccr6-/- mice we performed a time course mortality study to evaluate
whether differences observed in Ccr6-/- mice were associated with changes in liver injury. No
mortality was observed at 4 hours after clodronate plus CCl4 injection. Surprisingly, although
mortality was higher in Ccr6-/- mice at 8 (0% wt vs. 25% Ccr6-/- mice) and 12 hours (25% wt vs.
40% Ccr6-/- mice) transaminase levels were not different between Ccr6-/- and wt animals. More-
over, gene expression levels of Treg (Foxp3), proliferation (Cyclin D1), pro-inflammatory
(Icam1, Il6), pro-apoptotic (Bax), anti-apoptotic (Bcl2) and pro-fibrogenic (Tgf-β) genes at 4, 8
and 12 hours did not change between Ccr6-/- and wt in macrophages-depleted surviving mice
after single CCl4 injection (S3 Fig).
Chemokine receptor CCR6 expression correlates with clinical features
of alcoholic hepatitis
Since CCR6 expression was found to regulate the liver inflammatory response to injury, we
evaluated the expression of CCR6 in AH, a disease with an important inflammatory response
and increased expression of CCL20. CCR6 expression was evaluated in a cohort of 46 well-
characterized patients with AH with already reported levels of CCL20 [19]. Although we did
not observe a statistically significant increase in CCR6 hepatic expression in patients with AH
(S4A Fig) compared to normal liver, we found that the expression of CCR6 correlated with the
hepatic expression of CCL20 (Fig 5A), the only chemokine that reportedly binds and activates
this receptor (p<0.001). In addition, we further investigated the protein expression of CCR6 in
AH patients liver tissue. Interestingly, we found that CCR6 was mainly detected in inflamma-
tory cells, especially in mature lymphocytes, but also it was found to be expressed in some
hepatocytes (Fig 5B). However, as observed by a pathologist, not all lymphocytes were positive
for CCR6, suggesting that probably, only a specific subset of these cells express CCR6 in this
specific clinical condition.
Surprisingly, we found that CCR6 hepatic expression was inversely correlated with the
amount of infiltrated polymorphonuclear cells (PMN) in patients with AH, showing higher
levels of CCR6 expression in patients with mild PMN infiltration with respect to those with
severe PMN infiltration (Fig 5C) (p = 0.036). Moreover, in patients with AH, CCR6 hepatic
expression positively correlated with important prognostic scores such as METAVIR
(p = 0.014) (Fig 5D), MELD (Model for End-stage Liver Disease) (p = 0.005) (Fig 5E), and
Maddrey’s (p = 0.002) and ABIC (p = 0.043) scores (S4B and S4C Fig).
Fig 3. Effects of Ccr6 depletion on the hepatic inflammatory infiltrate. (A) Representative FACS plots of inflammatory cells isolated from two-week
CCl4-treated mice livers showing percentage of CD4+T cells in wt andCcr6-/-mice (5.56±2% in wt vs. 13.14±4.7% in Ccr6-/- of total hepatic mononuclear
cells) (p<0.005), CD4+FOXP3+ (19±8.3% in wt vs. 22±5.5% inCcr6-/- of CD4+T cells), CD4+IL17+ cells (2.85±1.5% in wt vs. 0.44±0.3% in Ccr6-/- of
CD4+ cells) (p = 0.005). (B) Representative MPO immunostaining of liver sections of wt andCcr6-/- (KO) mice treated for two weeks with CCl4 (x200
magnification); MPO quantification of positive-stained areas is shown in the graph (*p<0.05 compared to wt). (C) Representative FACS plots showing
MHCII+CD11c+ cells in wt andCcr6-/- mice in the absence of liver injury (3.05±0.5% in wt vs. 2.15±0.4% in Ccr6-/- of total hepatic mononuclear cells)
(p<0.05). (D) after chronic CCl4-induced liver damage (5.91±1.5% in wt vs. 3.92±1.5% inCcr6-/- of total hepatic mononuclear cells) (p<0.05).
doi:10.1371/journal.pone.0145147.g003
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Discussion
Inflammatory cell homeostasis and recruitment are essential for a well-controlled tissue
inflammatory response. In this study we investigated the role of the CCR6 receptor in the
hepatic homeostasis and recruitment of inflammatory cell populations and in the regulation of
liver injury. Using Ccr6 deficient mice, we showed that CCR6 deficiency had an important
impact on inflammatory cell recruitment causing exacerbated inflammation and fibrosis.
Moreover, in AH, a disease characterized by a high expression of CCL20, the only ligand of
CCR6 described, CCR6 expression correlates with disease severity. Our results reveal CCR6 as
an important cytokine-receptor in the regulation of the inflammatory cell recruitment and the
modulation of liver damage.
Chemokines and chemokine-receptors have been described to play an active role in liver
diseases by modulating hepatic inflammatory recruitment [11, 19, 28–30] and have been pro-
posed as potential therapeutic targets [4, 6, 31, 32]. In a recent study we showed that CCL20 is
a pleiotropic chemokine highly expressed in AH and mediates liver injury, inflammation and
fibrosis [19]. Moreover, recent studies have linked CCL20 expression with CCR6-dependent
recruitment of inflammatory cells, which modulate liver response to injury and liver regenera-
tion [28, 33]. We have now assessed the expression and the role of CCR6 in the context of liver
injury to understand the weight of CCR6-dependent recruitment of inflammatory cells in liver
disease.
Frequently, strategies to inhibit a particular chemokine and chemokine-receptor pathway
are not fully effective due to their high promiscuity. To overcome this limitation, in this study
we used Ccr6 knockout mice in order to ensure complete blockage of CCR6-dependent recruit-
ment. Although our system does not prevent inflammatory cell population to be recruited
through other receptors, our results indicate that CCR6 has an effect on inflammatory cell
recruitment in the healthy liver and during liver injury. This is important since changes in
inflammatory cell populations and their phenotype may be of key importance for liver
response to injury. Interestingly, we observed that the hepatic Ccr6-dependent inflammatory
recruitment affects several cell populations including neutrophils, T cells, dendritic cells and
macrophages. Moreover, as detected by Ki67 immunohistochemistry, we also observed an
increased proliferation of inflammatory cells in Ccr6-/- mice compared to wt animals, confirm-
ing exacerbated inflammation in the absence of Ccr6.
T lymphocytes and particularly CD4+T cells (T helper) have been described to be involved
in the pathogenesis of chronic liver diseases affecting hepatocellular damage [6]. We observed
that the deficiency of the CCR6 receptor has an important effect on the populations of lympho-
cytes recruited in the liver after both acute and chronic liver injury. CCR6 deficiency does not
promote liver hepatocellular injury, however, LDH levels are increase after CCl4 treatment sug-
gesting a potential effect on extrahepatic organs. We have shown that CCR6 deficiency not
only mediates an increase in the recruitment of CD4+ positive cells but also determines a
reduction of IL17+ positive cells, remarking that CCR6 participates in the recruitment of T
helper cells in the liver in response to liver injury. Two recent studies provided important
Fig 4. Effect of macrophage depletion inCcr6-/-mice. (A) Representative F4/80 immunostaining of liver sections of wt andCcr6-/-mice injected with PBS
liposomes (vehicle) (n = 8) or clodronate liposomes (n = 13) followed by CCl4 acute liver injury (see S1 Text). (B) Representative H&E staining of liver
sections (x100 magnification) of wt andCcr6-/-mice injected with clodronate liposomes followed by CCl4 acute liver injury (see S1 Text). (C) Icam1, Il6, Tnf-
α, Nos2,Mcp1 andCol1a1 hepatic gene expression inCcr6-/- (KO) mice injected with PBS liposomes or clodronate liposomes in presence (1xCCl4–
injected) or absence (vehicle, corn-oil injected) of CCl4-induced acute liver damage (see S1 Text) (*p<0.05). (D) Icam1, Il6, Tnf-α andCol1a1 hepatic gene
expression in wt andCcr6-/- (KO) mice injected with clodronate liposomes and vehicle- (corn oil) or 1xCCl4 (*p<0.05 with respect to wt). (E) ALT, AST and
LDH serum levels in wt andCcr6-/- (KO) mice in the presence (PBS liposomes injected) and absence (clodronate liposomes injected) of macrophages in
animals with CCl4-induced acute liver injury (*p<0.05).
doi:10.1371/journal.pone.0145147.g004
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information on the mechanisms involved in the role of the CCL20-CCR6 axis in liver injury
showing that the recruitment of γδT cells restricted liver injury and promoted liver regenera-
tion [28, 33]. The adoptive transfer of wt γδT cells into Ccr6 deficient mice reduced hepatic
inflammation and fibrosis in chronic injury, and the recruitment of γδT cells increased the pro-
duction of IL17, which has been shown to promote hepatocyte proliferation and regeneration
in partial hepatectomy [28, 33]. Our findings are in accordance with these previous studies by
showing an association between CCR6-dependent inflammatory recruitment and the progres-
sion of liver inflammation and fibrosis. However, an important finding of our study is the
observation that macrophages are differentially recruited in Ccr6 deficient and wtmice. Fur-
thermore, the phenotype of macrophages in healthy and injured liver of Ccr6 deficient mice is
altered and adopts a more inflammatory M1 profile.
Macrophages are a heterogenic population in the liver and important players in both acute
and chronic liver injury. A key feature of macrophages is their plasticity and the acquisition of
a M1 pro-inflammatory and M2 anti-inflammatory phenotype in response to inflammatory
mediators, which have been shown to play an important role in fibrosis progression and resolu-
tion [17]. In this study we showed that the number of macrophages in non-injured Ccr6-/- mice
is increased, and that the liver showed an increased expression of M1 markers Tnf-α, Il6 and
Mcp1. Moreover, although the number of macrophages did not vary between wt and Ccr6 defi-
cient mice after liver injury, Ccr6-/- mice presented an increased expression of hepatic M1 cyto-
kines and an increased number of hepatic freshly infiltrating monocyte-derived macrophages
as assessed by qPCR and flow cytometry. Whether, macrophages from Ccr6-/- mice show a dif-
ferent phenotype or a different response to injury as compared to those from wt animals is not
addressed in this study and will deserve further investigation. We also observed a decreased
number of MHCII+CD11c+ positive cells (dendritic cells) in Ccr6-/- mice compared to wt in
the absence and after liver injury. Since CD11c might be also present in liver macrophages
under inflammatory conditions [34], in our study we have used a combination of CD11c with
MHCII, which are both highly expressed in classical/mature dendritic cells [35, 36] to better
discern mature dendritic cells and macrophages.
To investigate if the increase in macrophage number is responsible for the exacerbated
inflammatory response and increased fibrosis observed in Ccr6-/- mice, we depleted the macro-
phages in healthy and injured mice. As expected, the depletion of macrophages in Ccr6-/- mice
induced a decrease in the expression of inflammatory mediators to levels comparable to wt
mice or even lower, suggesting that the unbalanced macrophage number and phenotype con-
tributed to the altered hepatic inflammatory state in Ccr6-/-. Surprisingly, Ccr6-/- mice depleted
of macrophages were extremely susceptible to liver injury, which precluded us performing a
chronic liver injury model. However, the analysis of macrophage-depleted Ccr6-/- mice at early
time points after CCl4 administration, showed no effect on the extent of liver injury or inflam-
matory response as assessed by transaminase levels and pro-inflammatory cytokines expres-
sion. Whether macrophages in combination with CCR6-recruted cells have a protective effect
to liver injury or promote a regenerative stimulus deserves further investigations.
Due to the overexpression of chemokine CCL20 in patients with AH, we also checked the
hepatic expression of the receptor CCR6 in the same cohort of patients. Although we did not
find significantly increased levels of CCR6 in the liver of these patients, as expected, CCR6
hepatic expression positively correlated with CCL20 hepatic expression. Interestingly, CCR6
Fig 5. CCR6 hepatic expression and correlation with clinical features of AH. (A) Correlation betweenCCR6 andCCL20 hepatic gene expression in
patients with AH (n = 46) (p<0.001). (B) Representative image of CCR6 staining in a liver sample from a patient with AH (magnification x200). (C) Association
betweenCCR6 hepatic gene expression and hepatic PMN infiltration (p = 0.036). (D) Correlation betweenCCR6 hepatic expression and the METAVIR
prognostic score. (E) Correlation betweenCCR6 hepatic gene expression and the MELD score in patients with AH (n = 46) (p<0.005).
doi:10.1371/journal.pone.0145147.g005
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hepatic expression was observed in inflammatory cells within the fibrous septa and some hepa-
tocytes. Moreover, its expression correlated with important clinical scores defining the severity
of the disease, suggesting a possible role of the CCL20/CCR6 axis in the pathogenesis of AH.
This study, together with previous data investigating the role of CCL20 in liver disease, iden-
tifies the CCL20/CCR6 pathway as an important player in liver disease. While CCL20 expres-
sion exerts an increase in liver injury and inflammation, here we show that the lack of CCR6
exacerbates the inflammatory cell response. This apparent opposite effects may be due to sev-
eral reasons: the fact that CCL20 may be a ligand to other non-identified receptors, an ineffi-
cient signaling of CCL20 in CCR6 deficient animals, an altered recruitment of CCR6
inflammatory cells, or the alteration of the phenotype of inflammatory cells lacking the CCR6
receptor. Further studies will have to elucidate these open questions regarding the mechanisms
driving the combined effects of CCL20 and CCR6 in the context of liver injury.
Here we show that deficiency of the CCR6 receptor mediates an alteration in inflammatory
cell recruitment, which results in a worsened inflammatory and fibrogenic liver response to
injury. Moreover, we highlight the prominent role of macrophages in this exacerbated
response. Altogether, these results suggest that CCR6 deficiency exacerbates liver injury by
increasing macrophage recruitment and promoting an inflammatory phenotype. Defining the
role of chemokines and chemokine-receptors such as CCL20 and CCR6 in liver injury is of par-
amount importance to better understand liver disease and to develop new targeted therapeutic
strategies.
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